Geraniol,a natural monoterpene,ameliorates hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats

Context: Geraniol, an acyclic monoterpene alcohol is found in medicinal plants, is used traditionally for several medical purposes including diabetes.

Objectives: The present study evaluates the antihyperglycemic potential of geraniol on key enzymes of carbohydrate metabolism in streptozotocin (STZ)-induced diabetic rats.

Materials and methods: Diabetes was induced in experimental rats, by a single intraperitoneal (i.p) injection of STZ [40?mg/kg body weight (b.w.)]. Different doses of geraniol (100, 200 and 400?mg/kg b.w.) and glyclazide (5?mg/kg b.w.) were administrated orally to diabetic rats for 45?days. Body weight, food intake, plasma glucose, insulin, blood haemoglobin (Hb), glycosylated haemoglobin (HbA_1c), hepatic glucose metabolic enzymes and glycogen were examined.

Results: The LD₅₀ value of geraniol is 3600?mg/kg b.w. at oral administration in rats. Administration of geraniol in a dose-dependent manner (100, 200, 400?mg/kg b.w.) and glyclazide (5?mg/kg b.w.) for 45?days significantly improved the levels of insulin, Hb and decreased plasma glucose, HbA_1C in diabetic-treated rats. Geraniol at its effective dose (200?mg/kg b.w.) ameliorated the altered activities of carbohydrate metabolic enzymes near normal effects compared with two other doses (100 and 400?mg/kg b.w.). Geraniol treatment to diabetic rats improved hepatic glycogen content suggesting its anti-hyperglycemic potential. Geraniol supplement was found to preserve the normal histological appearance of hepatic cells and pancreatic β-cells in diabetic rats.

Discussion and conclusions: The present findings suggest that geraniol can potentially ameliorate key enzymes of glucose metabolism in experimental diabetes even though clinical studies used to evaluate this possibility are warranted.